Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions (NCT03492151)
Confocal Laser Endomicroscopy as an IMaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
🩺 Plain-English Summary (8th-Grade Level)
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as "gold standard" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Scottsdale Campus — Scottsdale, Arizona
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Mayo Clinic Scottsdale Campus — Scottsdale, Arizona
- Stanford Hospital — Stanford, California
- Yale School of Medicine — New Haven, Connecticut
- Parkview Hospital Randallia — Fort Wayne, Indiana
- The Johns Hopkins Hospital — Baltimore, Maryland
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- NYU Langone Health — Garden City, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Baylor College of Medicine — Houston, Texas
📞 Contact the Study Coordinator
Phone: (614) 293-1056
Email: Megan.Fry@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Cyst
- Safety and Efficacy of EUS-RFA in the Treatment of Pancreatic Lesions: A Prospective Registry — Houston, Texas
- Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms — Basking Ridge, New Jersey
- UCSF PANC Cyst Registry — San Francisco, California
- Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer — Stanford, California
- Blood and Cystic Fluid From Patients Undergoing Surgery for Worrisome Pancreatic Cysts — Newport Beach, California
- Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection — Omaha, Nebraska
Explore by condition: All Pancreatic Cyst clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.